NCT05491759

A Study to Determine Optimal Absorption of Single Dose Omega-3

A Randomised Three-way Cross Over Study to Determine the Optimal Absorption of an Omega-3 Supplement Administered as a Single Oral Dose to Healthy Volunteers

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

This is a randomised three-way cross over study comparing the optimal absorption of a single dose of fish oil using 3 different forms to one another on increasing blood concentrations of fatty acids in 24 healthy adult participants aged 19 years and over.

Conditions

• Optimal Gastrointestinal Absorption of Omega-3

Interventions

Type	Name	Description
DRUG	Product 1 - AquaCelle Fish Oil Triglyceride	1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
DRUG	Product 2 - AquaCelle Fish Oil Ethyl Ester	1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
DRUG	Product 3 - Standard Fish Oil Triglyceride	1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).

Timeline

• Start date: 2022-08-04
• Primary completion: 2022-09-28
• Completion: 2022-09-28
• First posted: 2022-08-08
• Last updated: 2023-10-24

Locations

1 site across 1 country: Australia